EUVIMEDEUVIMED entdecken
Übersichtsarbeit

P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)

Xin-Yu Chen, Kai Wang, Jie Jia, Xiao-Tian Kong, Huan-Qiu Li iD, Sheng Tian iD

Expert Opinion on Therapeutic Patents · 2025

DOI: 10.1080/13543776.2025.2467683 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Opinion on Therapeutic Patents, 2025. Verfasst von Xin-Yu Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Purinergic P2Y Receptor Antagonists, Fibrinolytic Agents, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Priority Academic Program Development of the Jiangsu Higher Education Institutes, Suzhou Science and Technology Development Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: P2Y12 receptor (P2Y12R) is a G protein-coupled receptor that plays a crucial role in regulating platelet activation and aggregation. P2Y12R is involved in various processes such as renal fibrosis, cancer, ischemic disease, and related complications, making it an appealing target for therapeutic interventions. Over the past decade, the discovery and development of P2Y12R antagonists have significantly advanced, offering novel treatment options that improve clinical outcomes. AREAS COVERED: This review covers P2Y12R antagonists reported in patents issued in the online databases of the World Intellectual Property Organization and the European Patent Office from 2019 to 2024. This review introduces the development of existing antagonists and evaluates the therapeutic potential of these compounds. EXPERT OPINION: Reversible P2Y12R antagonists offer a potentially safer alternative to the currently dominant irreversible antagonists on the market, as they allow for more controlled platelet inhibition and can reduce the toxicity and adverse effects associated with conventional drugs. Importantly, the integration of computational drug design and molecular docking studies in the discovery and optimization of P2Y12R antagonists represents a significant advancement in precision medicine. This not only provides valuable structural scaffolds but also stimulates novel ideas for developing promising drugs that are both safe and efficacious.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purinergic P2Y Receptor AntagonistsFibrinolytic AgentsPlatelet Aggregation InhibitorsHumansPatents as TopicAnimalsReceptors, Purinergic P2Y12Drug DesignDrug DevelopmentMolecular Docking SimulationPrecision MedicinePlatelet Aggregation

Stichwörter der Autor:innen

P2Y12Rantagonistsantiplatelet activityischemic diseasevirtual screening

Substanzen

Purinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12Fibrinolytic AgentsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • College of Pharmaceutical Sciences, Soochow University, Suzhou, China.
  • College of Chemistry and Life Science, Beijing University of Technology, Beijing, China.
  • Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology, Suzhou Vocational Health College, Suzhou, China.
  • Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou, China.

ORCID-Profile: Huan-Qiu Li, Sheng Tian

Förderung

  • National Natural Science Foundation of China
  • Priority Academic Program Development of the Jiangsu Higher Education Institutes
  • Suzhou Science and Technology Development Plan Project

Zitieren

APA

Chen, X. Y., Wang, K., Jia, J., Kong, X. T., Li, H. Q., & Tian, S. (2025). P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present). Expert Opinion on Therapeutic Patents. https://doi.org/10.1080/13543776.2025.2467683

Vancouver

Chen XY, Wang K, Jia J, Kong XT, Li HQ, Tian S. P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present). Expert Opinion on Therapeutic Patents. 2025. doi:10.1080/13543776.2025.2467683

BibTeX
@article{Chen2025,
  author = {Chen, Xin-Yu and Wang, Kai and Jia, Jie and Kong, Xiao-Tian and Li, Huan-Qiu and Tian, Sheng},
  title = {P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)},
  journal = {Expert Opinion on Therapeutic Patents},
  year = {2025},
  doi = {10.1080/13543776.2025.2467683}
}
Kostenlos starten →